Alkermes plc (ALKS)
Largest Insider Buys in Sector
ALKS Stock Price History Chart
ALKS Stock Performance
About Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia …
Insider Activity of Alkermes plc
Over the last 12 months, insiders at Alkermes plc have bought $0 and sold $5.47M worth of Alkermes plc stock.
On average, over the past 5 years, insiders at Alkermes plc have bought $470,870 and sold $11.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 35,000 shares for transaction amount of $815,735 was made by Daglio David Angelo Jr. (director) on 2022‑11‑14.
List of Insider Buy and Sell Transactions, Alkermes plc
| 2024-12-09 | Sale | EVP R&D, Chief Medical Officer | 61,151 0.0384% | $32.07 | $1.96M | -2.27% | ||
| 2024-12-09 | Sale | director | 2,691 0.0017% | $31.85 | $85,708 | -2.27% | ||
| 2024-12-05 | Sale | EVP R&D, Chief Medical Officer | 9,221 0.0058% | $31.50 | $290,462 | -1.67% | ||
| 2024-12-04 | Sale | EVP R&D, Chief Medical Officer | 14,349 0.0088% | $30.77 | $441,550 | -1.13% | ||
| 2024-11-27 | Sale | SVP, Chief Commercial Officer | 5,208 0.0032% | $29.15 | $151,813 | +4.49% | ||
| 2024-11-11 | Sale | EVP R&D, Chief Medical Officer | 58,996 0.0363% | $30.08 | $1.77M | -1.99% | ||
| 2024-11-06 | Sale | EVP R&D, Chief Medical Officer | 10,471 0.0065% | $29.53 | $309,169 | +0.46% | ||
| 2024-03-18 | Sale | SVP, Chief Commercial Officer | 10,417 0.0064% | $28.10 | $292,740 | -2.43% | ||
| 2024-02-27 | Sale | VP, Finance (Interim PAO) | 2,559 0.0015% | $29.65 | $75,874 | -8.27% | ||
| 2024-02-15 | Sale | director | 2,690 0.0018% | $31.85 | $85,677 | -15.94% | ||
| 2023-06-08 | Sale | director | 2,638 0.0016% | $31.85 | $84,020 | -12.09% | ||
| 2023-06-07 | Sale | director | 2,800 0.0017% | $31.50 | $88,200 | -10.69% | ||
| 2023-05-30 | Sale | SVP, Chief Commercial Officer | 27,134 0.0163% | $28.93 | $784,862 | -4.59% | ||
| 2023-05-09 | Sale | director | 41,250 0.0252% | $31.24 | $1.29M | -9.28% | ||
| 2022-11-14 | director | 35,000 0.0218% | $23.31 | $815,735 | +23.30% | |||
| 2022-06-21 | Sale | SVP, Chief Commercial Officer | 7,474 0.0047% | $28.26 | $211,203 | -3.00% | ||
| 2022-05-17 | Sale | SVP, Corp Dev., Alkermes, Inc. | 50,000 0.03% | $29.15 | $1.46M | -9.67% | ||
| 2022-05-10 | Sale | SVP, Corp Dev., Alkermes, Inc. | 25,000 0.0154% | $27.22 | $680,380 | -0.78% | ||
| 2022-05-05 | Sale | Director and CEO, Alkermes plc | 93,747 0.0571% | $27.85 | $2.61M | -4.37% | ||
| 2022-05-03 | Sale | SVP, Corp Dev., Alkermes, Inc. | 25,000 0.0151% | $28.62 | $715,415 | -8.00% |
Insider Historical Profitability
| BLOOM FLOYD E | director | 127923 0.0791% | $29.71 | 1 | 13 | +9.38% |
| Daglio David Angelo Jr. | director | 80000 0.0494% | $29.71 | 1 | 0 | +23.3% |
| ANSTICE DAVID W | director | 73081 0.0452% | $29.71 | 1 | 4 | +44.33% |
| Stejbach Mark | SVP/Chief Comm Off, Alks Inc | 44013 0.0272% | $29.71 | 1 | 9 | +46.24% |
| DIXON WENDY L | director | 41300 0.0255% | $29.71 | 1 | 2 | +1.23% |
Institutional Investor Ownership
| BlackRock | $789.59M | 17.24 | 29.17M | -2.84% | -$23.12M | 0.02 | |
| The Vanguard Group | $545.76M | 11.91 | 20.16M | -3.79% | -$21.5M | 0.01 | |
| Wellington Management Company | $403.14M | 8.8 | 14.89M | -2.29% | -$9.45M | 0.07 | |
| State Street | $243.74M | 5.32 | 9M | -3.73% | -$9.45M | 0.01 | |
| T. Rowe Price | $225.39M | 4.92 | 8.33M | +421.83% | +$182.2M | 0.03 |